Author Archives: admin


Global Cell Therapy Market (2020 to 2025) – Growth, Trends, and Forecast – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The cell therapy market will show rapid growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine and rise in the number of clinical studies pertaining to the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. The emerging markets will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand for healthcare systems due to chronic disease has thus become a major concern. Healthcare expenditures greatly increase, with each additional chronic condition with greater specialist physician access, emergency department presentations and hospital admissions.

Therefore the increasing prevalence of chronic conditions, government assistance and numerous companies investing heavily in stem cell therapy research and development will help to stimulate the industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines pertaining to cell therapy research and manufacturing should positively impact industry growth.

Companies Mentioned

Key Market Trends

Allogeneic Therapies Segment Accounted for the Largest Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore there is an increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas is driving revenue generation.

Furthermore, the presence of a substantial number of approved products for clinical use has led to the large revenue share of this segment.

North America is Leading the Cell Therapy Market

North America is estimated to retain the largest share of the market due to the presence of strong regulatory framework in order to promote cellular therapy development, the existence of industry big shots, and high cost of therapies in the U.S. There is also the presence of leading universities that supports the research activities in the U.S. is one of the key factor driving the market for cell therapy in North America.

The Asia Pacific market is also increasing at a rapid rate due to the availability of therapies at lower prices coupled with growing awareness among the healthcare entities and patients pertaining the potential of these therapies in chronic disease management.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Chronic Conditions

4.2.2 Rising Adoption of Regenerative Medicine

4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies

4.3 Market Restraints

4.3.1 High Cost of Therapies

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Type

5.1.1 Autologous

5.1.2 Allogeneic

5.2 By Therapy

5.2.1 Mesenchymal Stem Cell Therapy

5.2.2 Fibroblast Cell Therapy

5.2.3 Hematopoietic Stem Cell Therapy

5.2.4 Other Therapies

5.3 By Application

5.3.1 Musculoskeletal

5.3.2 Malignancies

5.3.3 Cardiovascular

5.3.4 Dermatology & Wounds

5.3.5 Other Applications

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle-East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Anterogen Co., Ltd.

6.1.2 Tego Science

6.1.3 Chiesi Farmaceutici S.p.A.

6.1.4 Corestem Inc.

6.1.5 Pharmicell Co Ltd.

6.1.6 Fibrocell Technologies Inc

6.1.7 Nipro Corp

6.1.8 MEDIPOST

6.1.9 TiGenix (Takeda Pharmaceuticals)

6.1.10 Stempeutics Research Pvt. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/9qtcg2

Go here to read the rest:
Global Cell Therapy Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com - Business Wire

CC-486 Constitutes Standard of Care for Subset of Patients with AML – Targeted Oncology

Older patients with acute myeloid leukemia are traditionally treated with intensive induction chemotherapy and derive benefit, but responses are not durable, and the overall survival (OS) with this treatment in short. It was hypothesized by Guillermo Garcia-Manero, MD et al, that maintenance therapy for post-remission AML might improve upon survival in the patient population, and the phase 3 QUAZAR AML-001 clinical trial was designed to investigate the hypothesis.

The oral hypomethylating agent, CC-486 induced a statistically significant improvement in OS compared with placebo in patients with AML, according to results from QUAZAR AML-001 (NCT0175753). These study findings recently drove the FDAs decision to approve the drug as a maintenance treatment for adult patients with AML who achieved a first complete remission or with incomplete blood count recovery after intensive induction chemotherapy and who are unable to complete intensive curative therapy.

The OS observed with CC-486 in QUAZAR AML-001 was 24.7 months compared with 14.8 months with placebo (HR, 0.69; 95% CI, 0.55-0.86;P=.0009). In addition to the OS benefit, relapse-free survival (RFS) was improved with CC-486 at 10.2 months compared to only 4.8 months with placebo(HR, 0.65; 95% CI, 0.52-0.81;P=.0001). During the presentation of these findings at the 2019 American Society of Hematology (ASH) Annual Meeting, the investigators concluded that CC-482 is the first agent used in the maintenance setting to show statistically significant and clinically meaningful improvements in both OS and RFS in post-remission patients with AML.

In an interview with Targeted Oncology following the FDA approval of CC-486, Dr. Garcia-Manero, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the key findings from the QUAZAR AML-001 study and the importance of the FDA approval of CC-486 in post-remission AML.

TARGETED ONCOLOGY: It is known that azacitidine injection is effective for the treatment of AML, but why was is necessary to develop a new form of this drug?

Garcia-Manero: We refer to these drugs as hypomethylating agents. The issue with them is that if the patient responds to them, this requires therapy that could last for multiple months or years. We have 2 hypomethylating agents now, which are decitabine and azacitidine. The agents are usually given for five days a month or sometimes seven consecutive days a month.

This means some patients have to take IV or subcutaneous injections every week for the rest of their life.Because of this, weve been trying to develop an oral hypomethylating agent for about 50 years, and its exciting that we finally have it.

TARGETED ONCOLOGY: What was the rationale for the QUAZAR AML-001 clinical trial?

Garcia-Manero: This was a very interesting study where patients with AML that were in remission were treated in a randomized fashion with azacitadine tablets or a control. The problem with AML is relapse and there have been multiple trying this concept of maintenance therapies to see if some type of low-dose intensive chemotherapy approach would improve survival.

TARGETED ONCOLOGY: What were the key findings of the QUAZAR AML-001 study? What was the safety profile observed with CC-486 in this study?

Garcia-Manero: This is the first study where we see a survival benefit that is quite significant with the hypomethylating agent CC-486, which is a consolidation therapy approach rather than doing nothing.

The data are highly significant in terms of improvement in OS. It is close to 10 months which we have not seen in the past with almost no intervention. The only intervention performed was stem cell transplantation.

The toxicity profile of the compound was well tolerated. That said, these kinds of drugs are mild forms of chemotherapy and therefore can induce cytopenia or mild gastrointestinal toxicities.

TARGETED ONCOLOGY: Now that CC-486 is FDA approved, what will be the overall impact of this drug in the AML treatment landscape?

Garcia-Manero: Theres an interesting shift in the landscape because another oral hypomethylating agent (decitabine) was approved by the FDA last month. For CC-486, in particular, I think were going to have to decide what the role of the drug is outside its current indication of post-consolidation maintenance therapy because this CC-486 is not exactly like azacitadine, it has a different pharmacokinetic and pharmacodynamic profile. We are going to have to design new studies in AML and myelodysplastic syndrome. Right now, the role of CC-486 is clearly post-consolidation maintenance therapy.

TARGETED ONCOLOGY: How would you advise oncologists to use CC-486 in practice, now that is available?

Garcia-Manero: In my opinion, using for CC-486 in patients that have completed consolidation therapy, or who are not candidates for stem cell transplantation or had significant toxicity from consolidation, the data from QUAZAR constitute using CC-486 as the standard of care. I would advise using this maintenance approach for this patient population.

If a patient can undergo stem cell transplantation, that should be considered over CC-486. I think the future, we should also pay attention to particular genetic alterations of the patients because there may be a specific subset of patient mutated disease that may be candidates for other targeted agents instead of CC-486.

Reference:

Wei A,DohnerH, Pocock C, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation ofAzacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission.Blood .2019;134(suppl 2):LBA3.doi:10.1182/blood-2019-132405.

Read more:
CC-486 Constitutes Standard of Care for Subset of Patients with AML - Targeted Oncology

Stem Cell Therapy Market Research, Technology, Demand, Analysis, Services, Type and Global Industry Forecast 2025 | Anterogen Co., Ltd. (South Korea),…

Introducing the Stem Cell Therapy Market: Gauging the Scope This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Stem Cell Therapy Market. This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Stem Cell Therapy market. The intricately presented market report is in place to unravel all growth steering determinants, presenting a holistic overview and analytical delivery governing the realms of opportunity diversification, a thorough review of challenges and threats to plan and deliver growth driven business strategies.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

A thorough assessment of the various facets of the market including segmentation reveals that the market has been categorized into prominent segments enlisting type, technology, applications as well as end-user segments. The report illustrates a vivid diversification of the segments in order to encourage wise and remunerative business discretion in the Stem Cell Therapy market. Analysis by Type: Various fact-based details about the diverse product types are housed in this section of the report to well identify the segment that reckons high investment returns. Analysis by Application: In the successive sections of the report, readers are presented with elaborate details on various applications in accordance to end-user needs across regions.

Get a copy here: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Study on Table of Contents: Stem Cell Therapy Market Overview, Scope, Status and Prospect (2015-2020) covering COVID-19 Pandemic. Global Stem Cell Therapy Market Competition by Manufacturers Global Stem Cell Therapy Capacity, Production, Revenue (Value) by Region (2015-2020) Global Stem Cell Therapy Supply (Production), Consumption, Export, Import by Region (2015-2020) Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type Global Stem Cell Therapy Manufacturers Profiles/Analysis Stem Cell Therapy Manufacturing Cost Analysis Industrial Chain, Sourcing Strategy and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Global Stem Cell Therapy Market Effect Factors Analysis and Forecast (2020-2025)

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Investing in the Report: Know Why This report aims to holistically characterize and classify the Stem Cell Therapy market for superlative reader understanding A thorough evaluation to investigate material sources and downstream purchase developments are echoed in the report Elaborate references on purchaser needs, barrier analysis and opportunity assessment are also ingrained The report surveys and makes optimum forecast pertaining to market volume and value estimation

Shoot your queries here https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Go here to see the original:
Stem Cell Therapy Market Research, Technology, Demand, Analysis, Services, Type and Global Industry Forecast 2025 | Anterogen Co., Ltd. (South Korea),...

Covid-19 Impact on Global Cell Therapy Market 2020 Outlook: Industry Insights, Statistics, Shares and Forecasts to 2025 – The Daily Chronicle

Introduction & Scope: Global Cell Therapy Market

Global Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Cell Therapy market. Research analysts and industry experts through this report are also aiming to lend ample light on further essential determinants such as a meticulous review and analytical take of opportunity assessment, also encompassing threat and challenge analysis that constantly deter upward growth spurt in Cell Therapy market.

Leading Companies Reviewed in the Report are:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Get Exclusive Sample of Report on Cell Therapy market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/611

Gauging COVID-19 Impact

To enable mindful business discretion amidst catastrophic developments such as COVID-19 and its subsequent implications, this ready-to-refer research report on the global Cell Therapy market is designed to answer the queries pertaining to the pandemic to emerge from catastrophic implications.

This intensively compiled research report presentation is a versatile hub of innate knowledge factors such as sales volume and bulk production, pricing matrix and sales figures, overall growth review and margin, chances of growth in the future and their range amongst other additional growth determinants that influence growth in the Cell Therapy market.

Regional Analysis

Furthermore, the report helps as a expedient guide to design and instrument probable growth routing activities across select regional hubs in the Cell Therapy market. Frontline companies and their result-based growth approaches are also recruited in the report to emulate growth.

In addition to in its succeeding sectors of the report, this detailed presentation of the Cell Therapy market offers vigorous details on regional belts and expansion projects identifying potential growth possibilities.

Quick Read Table of Contents of this Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Global Cell Therapy Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

According to research inputs, this global Cell Therapy market is also likely to register a thumping growth of USD xx million in 2020 and is further anticipated to reach over xx million USD by the end of 2027, clocking at a steady CAGR of xx% through the forecast span, 2020-27. Expert opinion also suggests that the global Cell Therapy market is likely to tread on the road to recovery in the foreseeable future.

Five-Pointer Guide for Report Investment

* A rigorous, end-to-end review and analysis of the Cell Therapy market events and their implications

* A thorough compilation of broad market segments

* A complete demonstration of best in-industry practices, mindful business decisions and manufacturer activities that steer revenue sustainability in the global Cell Therapy market

* A complete assessment of competition spectrum, inclusive of relevant details about key and emerging players

* A pin-point review of the major dynamics and dominant alterations that influence growth in the global Cell Therapy market

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A. Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the rest here:
Covid-19 Impact on Global Cell Therapy Market 2020 Outlook: Industry Insights, Statistics, Shares and Forecasts to 2025 - The Daily Chronicle

Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette – Lake Shore Gazette

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/3253

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/3253

In recent time, increasing prevalence of chronic diseases and increasing funds from government organizations are some of the major drivers for global stem cell therapy market. In addition, rising awareness about stem cell therapies and increasing focus on stem cell research are also supporting in growth of global stem cell therapy market. However, less developed research infrastructure for stem cell therapies and ethical issues related to embryonic stem cells are some of the major restraints for global stem cell therapy market. In addition, complexity related with the preservation of stem cell also obstructs the growth of global stem cell therapy market.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/3253

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Salessales@persistencemarketresearch.com Websitehttps://www.persistencemarketresearch.com

See original here:
Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette - Lake Shore Gazette

ERC-funded postdoctoral position at the Institut of Human Genetics, – Nature.com

The University Hospital Heidelberg is one of the major healthcare centers in Germany. Our objective is the development of innovative diagnostics and therapies as well as their quick implementation for the patient. With about 10,700 employees in more than 50 specialized clinical departments with almost 2,000 beds, about 80,000 patients in part-time and full-time inpatient treatment as well as 1,000,000 patients in ambulant treatment are medicated each year.

JobID: P0025V280

Location: Institut of Human Genetics, INF 366, 69120 Heidelberg Contract: 2 years with extension possibilities, begin as soon as possible Salary: Competitive, subject to skills and experience

The newly created Nephrogenetics unit headed by Matias Simons is looking for an enthusiastic postdoc to join our research group at the Institute of Human Genetics of the University Hospital Heidelberg. The general interest of the lab is in the molecular mechanisms underlying hereditary kidney and metabolic diseases. Most of these diseases are caused by single-gene defects and thereby offer unique opportunities to decipher fundamental regulatory pathways of human physiology and to develop targeted diagnostic and therapeutic options. Recent publications include Marchesin et al, Cell Rep 2020; Bedin et al, J Clin Invest 2019; Goncalves et al, PloS Genetics 2018; Simons, JASN 2018; Rujano et al, J Exp Med 2017; Trepiccione et al, JASN 2016; Gleixner et al, Cell Rep 2014. We combine human genetics with several experimental approaches, including fly and mouse genetics, cell culture, microscopy and biochemistry. For more info on the lab see http://www.simons-lab.de.

We offer an exciting project aimed at exploring the role of random monoallelic expression in renal development and homeostasis. For this project, we invite applications from individuals with a solid background in molecular cell biology. Prior experience with stem cells (e.g. mouse ESCs), organoids, single cell RNA-seq, epigenetics and kidney research is an advantage but not a prerequisite. The projects will be carried out in a stimulating work environment with scientific collaborations within the institute, across the Heidelberg life science community (e.g. EMBL, DKFZ) and worldwide.

The successful applicant will have good communication and organisational skills and a PhD in a relevant area (or be in the final stages of completion). We also invite applications from research-oriented MDs. Candidates are expected to be highly motivated and to work independently with a strong work ethic. As we are an international lab, profictiency in English language is a requirement. Applications including a cover letter, a detailed CV including a publication list and contacts of up to three referees should be sent as soon as possible to matias.simons@med.uni-heidelberg.de

The University Hospital Heidelberg offers:

http://www.klinikum.uni-heidelberg.de/karriere

We stand for equal opportunities. People with disabilities are given priority with the same suitability. The university hospital aims at a general increase in the proportion of women in all areas and positions where women are underrepresented. Qualified women are therefore particularly encouraged to apply.

Read the original:
ERC-funded postdoctoral position at the Institut of Human Genetics, - Nature.com

Omeros Corporation : – Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients -…

SEATTLE - Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19.

The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients, was held on September 2, 2020 and included international experts in hematology, oncology and complement science. The panel was moderated by Sara Jane Demy, founder and chief executive officer of Demy-Colton. A replay of the panel can be viewed here (free registration required).

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients. Narsoplimab, Omeros' investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector of the lectin pathway of complement, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.

Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol. All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.

About Narsoplimab

Narsoplimab, also known as 'OMS721,' is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

Phase 3 clinical programs are in progress for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy, and in atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple late-stage clinical development programs focused on complement-mediated disorders, including COVID-19, and substance abuse. A rolling biologics license application for narsoplimab, the company's lead MASP-2 inhibitor, in hematopoietic stem cell transplant-associated thrombotic microangiopathy is being completed for submission to the U.S. FDA. Omeros also has a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros' proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely', 'look forward to,' 'may,' 'on track,' 'plan,' 'potential,' 'predict,' 'project,' 'prospects,' 'scheduled,' 'should,' 'slated,' 'targeting,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros' investigational product, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, availability and timing of data from clinical trials and the results of such trials, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by its Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of any new information, future events or otherwise, except as required by applicable law.

Contact:

Jennifer Cook Williams

Tel: 360.668.3701

Email: jennifer@cwcomm.org

(C) 2020 Electronic News Publishing, source ENP Newswire

Continue reading here:
Omeros Corporation : - Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients -...

Animal Stem Cell Therapy Market 2020 with Top Countries Data : Market Size, Growth, Segments, Revenue, Top Manufacturers and Forecast to 2024 -…

Animacel

Scope of the Animal Stem Cell Therapy Market Report:The classification of animal stem cell therapy includes dogs, horses and others. And the proportion of dogs in 2020 is about 50.42%, and the proportion is in increasing trend from 2013 to 2020.North America is the largest consumption region of animal stem cell therapy, with a consumption market share nearly 58.63% in 2020. Japan is the second largest supplier of animal stem cell therapy, enjoying production market share nearly 15.17% in 2020.

The worldwide market for Animal Stem Cell Therapy is expected to grow at a CAGR of roughly 38.3% over the next five years, will reach 110 million US$ in 2024, from 16 million US$ in 2019, According to a New Research study.

This report focuses on the Animal Stem Cell Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Report:Animal Stem Cell Therapy Market 2020

Report further studies the market development status and future Animal Stem Cell Therapy Market trend across the world. Also, it splits Animal Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Geographically,this report is segmented into severalkey regions, with sales, revenue, market share and growth Rate of Animal Stem Cell Therapy in these regions, from 2014 to 2024, covering

This Animal Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13837427

Major Points from Table of Contents:

1. Market Overview 1.1 Animal Stem Cell Therapy Introduction 1.2 Market Analysis by Type 1.3 Market Analysis by Applications 1.4 Market Dynamics 1.4.1 Market Opportunities 1.4.2 Market Risk 1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview 2.4.2 Animal Stem Cell Therapy Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B

3.Global Animal Stem Cell Therapy Sales, Revenue, Market Share and Competition By Manufacturer (2019-2020)

3.1 Global Animal Stem Cell Therapy Sales and Market Share by Manufacturer (2019-2020) 3.2 Global Animal Stem Cell Therapy Revenue and Market Share by Manufacturer (2019-2020) 3.3 Market Concentration Rates 3.3.1 Top 3 Animal Stem Cell Therapy Manufacturer Market Share in 2020 3.3.2 Top 6 Animal Stem Cell Therapy Manufacturer Market Share in 2020 3.4 Market Competition Trend

4.Global Animal Stem Cell Therapy Market Analysis by Regions

4.1 Global Animal Stem Cell Therapy Sales, Revenue and Market Share by Regions 4.1.1 Global Animal Stem Cell Therapy Sales and Market Share by Regions (2014-2019) 4.1.2 Global Animal Stem Cell Therapy Revenue and Market Share by Regions (2014-2019) 4.2 North America Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.3 Europe Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.4 Asia-Pacific Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 South America Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 Middle East and Africa Animal Stem Cell Therapy Sales and Growth Rate (2014-2019)

Get a Sample PDF of report:Animal Stem Cell Therapy Market 2020

5.Animal Stem Cell Therapy Market Forecast (2020-2024) 5.1 Global Animal Stem Cell Therapy Sales, Revenue and Growth Rate (2020-2024) 5.2 Animal Stem Cell Therapy Market Forecast by Regions (2020-2024) 5.3 Animal Stem Cell Therapy Market Forecast by Type (2020-2024) 5.3.1 Global Animal Stem Cell Therapy Sales Forecast by Type (2020-2024) 5.3.2 Global Animal Stem Cell Therapy Market Share Forecast by Type (2020-2024) 5.4 Animal Stem Cell Therapy Market Forecast by Application (2020-2024) 5.4.1 Global Animal Stem Cell Therapy Sales Forecast by Application (2020-2024) 5.4.2 Global Animal Stem Cell Therapy Market Share Forecast by Application (2020-2024)

6.Sales Channel, Distributors, Traders and Dealers 6.1 Sales Channel 6.1.1 Direct Marketing 6.1.2 Indirect Marketing 6.1.3 Marketing Channel Future Trend 6.2 Distributors, Traders and Dealers

7.Research Findings and Conclusion

8.Appendix 8.1 Methodology 8.2 Data Source

Continued..

Purchase this report (Price3480 USD for a single-user license) https://www.360researchreports.com/purchase/13837427

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us: Name: Mr. Ajay More Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Smart Airport Solutions Market 2020 : Global Industry Analysis by Top Countries Data, Potential Growth, Key Players, Latest Trends and Forecast to 2026

Aviation MRO Software Market Size 2020 Growing Rapidly with Latest Trends, Market Size with Top Countries Data, Investment Opportunities, Share, Revenue, Demand and Forecast to 2026

Materials Need in 5G Market 2020 : Top Countries Data, Industry Analysis, Size, Share, Growth, Trends, and Forecast to 2026

More here:
Animal Stem Cell Therapy Market 2020 with Top Countries Data : Market Size, Growth, Segments, Revenue, Top Manufacturers and Forecast to 2024 -...

Editorial: UT Health’s new teaching hospital will boost region – Laredo Morning Times

Express-News Editorial Board

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Editorial: UT Healths new teaching hospital will boost region

A planned 144-bed teaching hospital on the UT Health San Antonio campus slated to open in the spring of 2024 will boost enrollment for many health programs so crucial for the region and state.

The medical school alone could see an increase of 22 students in each enrollment class. The number of medical residents could grow by 100 to 130 slots by 2027. Currently, 1,000 residency slots are offered through UT Health San Antonio.

This is great news for medical and other students training for health professions who want to complete their education in Texas. It will help address the shortage of providers in Bexar County and across the state. Historically, many doctors remain in the communities where they complete their medical training.

The San Antonio hospital would become the fourth operated by the University of Texas System. The others are in Dallas, Galveston and Tyler.

Most of the UT System health science centers have partnerships with independently managed hospitals in their communities.

Most new hospital projects arrive with much fanfare. This project has been quietly moving along over the past year with little public awareness or discussion.

The University of Texas System regents last month placed the nearly $400 million project on its capital improvement program and are expected to appropriate construction funds at their November meeting.

The hospital will be located on 12 acres in the South Texas Medical Center provided by the San Antonio Medical Foundation. The eight-story hospital will be adjacent to the Mays Cancer Center, formerly known as the Cancer Therapy and Research Center. The jointly run UT Health San Antonio-MD Anderson program is a National Cancer Institute-designated research center. The hospital and the cancer center will be connected by a skybridge.

A 530-space parking garage is also included in the project.

Background information provided to the regents describes a high-acuity hospital offering treatment programs in cancer, neurosciences, orthopedics, urology, thoracic surgery and bariatrics.

A distinct, competitive advantage of the hospital will be the unique leading-edge therapies and early-phase clinical trials in the many disciplines in which the university has expertise, including immunologic and stem cell therapies in oncology and diabetes, the backgrounder states.

The construction of a second teaching hospital in San Antonio raises concerns about the multibillion-dollar investment taxpayers have made in the Bexar County Hospital District, which includes University Hospital and some two dozen University Health System clinics.

University Hospital has long been the primary teaching hospital for UT Health San Antonio, and much of its recent expansion including the new 400-bed Womens and Childrens Hospital now under construction alongside University Hospital has been in large part to accommodate the patients seen by UT Health San Antonio doctors.

Will the two be duplicating services and competing for patients?

UT Health San Antonio President William L. Henrich and Bexar County Judge Nelson Wolff said the two hospitals will work in partnership. The hospital district and UT officials are negotiating a memorandum of understanding to that effect, Wolff said.

Henrich said the new hospital will not replicate any services and will complement what is currently offered. He said the new facility will allow for the expansion of the health science centers three primary missions clinical care, biomedical research and education.

Our clinical practices have been growing 8 to 10 percent a year, Henrich said. We have about $300 million in research on campus, and we need more access to clinical trials. Sophisticated clinical trials in cancer, rheumatology, gastroenterology and this hospital will afford us the opportunity to carry out those trials, and that will be a unique feature of this hospital.

In addition, the new hospital is expected to create 750 to 850 new jobs.

This is an important project for San Antonio and Texas. It will expand higher education opportunities, help address the doctor shortage in the state and provide a lift to the local economy by creating skilled jobs.

We look forward to a thriving partnership between UT Health and the University Health System.

Continued here:
Editorial: UT Health's new teaching hospital will boost region - Laredo Morning Times

Mum’s message to the complete stranger who saved her son’s life – LincolnshireLive

A mum says the surprise baby she feared she would lose because of a rare genetic disorder is now living a normal life thanks to a bone marrow transplant from a complete stranger.

Former clinical psychologist Zoe Alderson has told how her son Henry was diagnosed with a rare genetic disorder, affecting just 125 people in the UK meaning he needed monthly blood transfusions.

But everything changed in April 2019 when Henry who has Diamond Blackfan Anaemia (DBA), which is caused by the bone marrow failing to produce red blood cells received a successful bone marrow transplant.

Zoe, 33, of Harwich, Essex, said he went from relying on transfusions to stay alive to having the blood count of a normal child his age, adding: We have no idea who provided the bone marrow, but not a day goes by when we dont think about that person. We will be forever in their debt.

At one point, it felt like we would never have a normal life, now you cant tell Henry apart from any other happy four-year-old.

Zoes own health problems began with fatigue, headaches and irregular periods throughout her teens.

But, in 2004, when she saw her doctor after her breasts began lactating, a blood test revealed she had higher than normal levels of the hormone prolactin. Amongst other things, it encourages the growth of breasts and lactation during pregnancy.

I didnt have a clue what was wrong with me, she explained.

I wrote it off as being stressed and nothing more.

Referred to Colchester Hospital in Essex in November 2004, an MRI scan revealed she had a benign 1cm tumour on her pituitary gland, at the base of her brain and was put on a prolactin inhibitor which she still takes to this day and, within six months, the tumour shrank to 3mm.

Doctors told me it was classed as a brain tumour, but I didnt need to panic, she continued. They said I might face some difficulty getting pregnant, though.

My periods were so irregular afterwards, that I never expected to conceive.

I wasnt that bothered, either, as I was just happy to be told the tumour was benign.

Meeting her husband Craig, 40, a graphic design company manager, at a work Christmas do in December 2007, within a year they moved in together.

But, firmly on a career path, they flew to Mombasa, Kenya, for an intimate wedding with their nearest and dearest on March 17, 2010 and thoughts of having children could not have been further from their minds.

Zoe said: We really werent fussed, or thats what we told ourselves.

She continued: We were both career driven and in our prime. Wed never even discussed the possibility of IVF or adoption it just wasnt on the radar.

But all that changed in January 2015, when Zoe was plagued with morning sickness.

I hadnt had a period for years, she said.

But Id been sick for a solid few days.

She continued: At first, I dismissed it as a bug, but when it lasted over a week, I thought I should do a pregnancy test before I saw a doctor.

I picked one up from the supermarket and when it came back positive, I just sat in the bathroom having a bit of a cry.

It was such a shock, it was just crazy.

She continued: Craig was absolutely thrilled, though, for someone who had said he wasnt fussed about having a baby.

But soon Zoe was haunted by the feeling that something wasnt right, with the pregnancy.

Then, at the 12-week scan, in early April 2015, the couple were told their baby showed signs of a genetic defect and was unlikely to survive to full-term, after finding a worrying amount of fluid around his head which is often an indicator of chromosomal defects in a foetus, according to the NHS.

Zoe said: Craig, ever the optimist, was convinced wed walk in and everything would be fine and dandy.

But moments after finding the heartbeat, the womans face dropped and before I knew it there were five medics huddled around the screen looking at the scan.

We were asked to wait down the corridor where doctors explained there was a high chance the baby had a genetic defect and was unlikely to survive for two more weeks.

Given chorionic villus sampling (CVS) a prenatal test to detect birth defects after three days the results came back negative for the most common conditions, but further testing for rarer defects left the expectant parents playing an agonising waiting game.

It felt like we had already written off our baby at that point, said Zoe.

We were carrying out the testing as an insurance policy, to see if there was a chance we could pass on any faulty genes in the future.

She continued: We were offered a termination but decided to let nature take its course.

And nature clearly had a positive plan for their baby boy, who continued to grow at a healthy rate.

We hit 14 weeks, then 20, then 24 and somehow we even made it to 36 weeks, Zoe said.

She continued: We still didnt have the results back from the genetic screening, but making it so far surprised everyone.

The consultant was amazed, he said hed never seen such a poorly foetus survive to this point.

But, just days after the milestone scan, Zoe could not feel the baby moving and rushed to Colchester Hospital, where a scan showed he was in distress.

Concerned, doctors performed an emergency C-section, delivering baby Henry on November 20, 2015.

When Henry was born we didnt know what was wrong with him still, said Zoe.

He let out a cry, but was ghostly white and was rushed to neonatal intensive care.

His pale complexion meant doctors assumed Henry had suffered from a placental haemorrhage in the womb, with a blood test showing he had a low red blood cell count.

Placed in an induced coma, the tot spent three weeks in intensive care, receiving three blood transfusions, to build up his red blood count.

I didnt get to see him on the day he was born, Zoe recalled. But I sent Craig down right away to keep an eye on him.

She continued: After the blood transfusions, he looked like a proper baby again and I couldnt wait to get him home.

Discharged at the beginning of December, the new parents were told to bring Henry in at the first sign of anything unusual.

He screamed around the clock and would not take to the bottle, but it was only when Henry turned deathly pale, on Christmas Eve, that the couple rushed him back to the hospital, where further tests revealed his red blood cell count was dangerously low leading to another transfusion.

For the next three months, every month, the couple would return to the hospital for Henry to receive a blood transfusion until, at four months old, he had a bone marrow biopsy.

Up until that point, all they could tell us was that Henry was anaemic, but that they didnt know why, Zoe explained.

The consultant examined the biopsy straight away and said it looked like he had DBA.

She continued: It was the first time wed heard of it, but as soon as we got home and Googled it, wed basically diagnosed Henry ourselves.

Two months later, by then six months old, his CVS results made the diagnosis official.

And, from then onwards, little Henry needed a blood transfusion every month with doctors telling his parents this would continue for the rest of his life.

Zoe said: It felt like Groundhog Day. After the transfusion hed be full of energy and behaving like a normal child.

But slowly, as the days passed, you could literally see the life draining out of him.

It sounds awful, but by the end of the month he really did look dead.

When he reach 18 months old, the couple were told Henrys body was suffering from an iron overload, because of his numerous blood transfusions.

To avoid iron poisoning which can cause severe damage to major organs he began taking iron chelation drugs, to remove the excess mineral from his body.

Administered through an IV, which Henry was hooked up to every night, Zoe said: It was such a difficult period for us.

She continued: It was bad enough seeing him deteriorate each week, without having to start sticking a needle into him every night as well.

He hated it at the time, but was fine during the day. Looking back, he was remarkably brave.

But when Zoe was told in February 2019 that he would need to be hooked up to the iron chelation machine 24 hours a day, she put her foot down.

Thats when I drew the line, she said. It wasnt fair expecting that of a child and I said I wanted them to look into alternatives.

Thats when doctors said Henry would be eligible for a bone marrow transplant.

After that, by then aged three, things moved quickly and, just six weeks later, Henry was matched with a tissue donor.

Then, in the last week of April 2019, he had chemotherapy to wipe out his existing bone marrow, before having a central line fitted, allowing the new stem cells to pass through his blood stream.

Put on immunosuppressants a type of medicine which stop the body from rejecting donor tissue for 12 months, Zoe said she witnessed a miracle, as she slowly got her boy back.

He hasnt needed a blood transfusion since he had the bone marrow donation, she said. Hes a completely different child.

She continued: Hes full of energy around the clock now not just for a few days a month.

I dont think we realised just how poorly he had been for the last four years until he recovered. That had become our normal.

Taken off immunosuppressants in May 2020, a month later, blood tests revealed that Henry had the blood count of an average four-year-old.

For his whole life hes been in and out of hospital and now, finally, he can start to live like any other kid, said Zoe.

Ringing the end of treatment bell was such a big deal for all of us.

It felt like the end of that chapter in our lives.

Desperate to raise awareness of DBA and the importance of bone marrow donation, Zoe now has an important message she wants to send to whoever saved her sons life.

Were so grateful to whoever it was that donated their bone marrow for Henry, she said.

To anyone else out there who isnt on the donor register, please sign up.

She continued: All it takes is a bit of your spit sent in the post and it could quite literally save someones life.

Go here to read the rest:
Mum's message to the complete stranger who saved her son's life - LincolnshireLive